Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer discovery

Showing results (881-890 of 4,265) with videos related to

Pageof 427
Sort By:
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|May 17, 2018
9/11 Firefighters at Risk for Multiple Myeloma
Cancer Discovery|May 18, 2018
Little Benefit to Breakthrough Cancer Drugs
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Cancer Discovery|May 6, 2018
Q&A: Ned Sharpless on His Vision for NCI
Cancer Discovery|August 18, 2018
Fundamental Mechanisms of Immune Checkpoint Blockade TherapySpencer C Wei, Colm R Duffy, James P Allison
Cancer Discovery|June 13, 2019
Merck Buys Maker of HIF2α Inhibitor
Cancer Discovery|June 14, 2019
AMG 510 First to Inhibit "Undruggable" KRAS
Cancer Discovery|October 17, 2012
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separationLivio Trusolino, Andrea Bertotti
Cancer Discovery|October 17, 2012
Setting the stage for cancer startups
Pageof 427

Showing results (881-890 of 4,265) with videos related to

Sort By:
Pageof 427
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|May 17, 2018
9/11 Firefighters at Risk for Multiple Myeloma
Cancer Discovery|May 18, 2018
Little Benefit to Breakthrough Cancer Drugs
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Cancer Discovery|May 6, 2018
Q&A: Ned Sharpless on His Vision for NCI
Cancer Discovery|August 18, 2018
Fundamental Mechanisms of Immune Checkpoint Blockade TherapySpencer C Wei, Colm R Duffy, James P Allison
Cancer Discovery|June 13, 2019
Merck Buys Maker of HIF2α Inhibitor
Cancer Discovery|June 14, 2019
AMG 510 First to Inhibit "Undruggable" KRAS
Cancer Discovery|October 17, 2012
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separationLivio Trusolino, Andrea Bertotti
Cancer Discovery|October 17, 2012
Setting the stage for cancer startups
Pageof 427